| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324745 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11202778 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11298356 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
Phyrago is owned by Nanocopoeia.
Phyrago contains Dasatinib.
Phyrago has a total of 3 drug patents out of which 0 drug patents have expired.
Phyrago was authorised for market use on 05 December, 2023.
Phyrago is available in tablet;oral dosage forms.
Phyrago can be used as use of dasatinib for treatment of newly diagnosed adults with ph+ cml in chronic phase, when coadministered with a gastric acid reducing agent, use of dasatinib for treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib, when administered at elevated gastric ph.
The generics of Phyrago are possible to be released after 22 January, 2041.
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 05 December, 2023
Treatment: Use of dasatinib for treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib, when administered at ...
Dosage: TABLET;ORAL
PHYRAGO family patents
